Evive Biotech and Acrotech Biopharma receive FDA approval of Ryzneuta

AstraZeneca launches health-tech business ‘Evinova’

Evinova will operate as a separate health-tech business within AstraZeneca

BioPhy launches AI platform to accelerate the drug development market

The company has raised US$4.5 million in funding for its AI operating system

Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-mutant advanced non-small cell lung cancer

Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients

Daiichi Sankyo, Merck collaborate to develop and commercialize three Daiichi Sankyo DXd ADCs

Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months

ImmunoACT announces the approval of India's first CAR-T cell therapy 'NexCAR19'

NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy

GlobalData predicts product cannibalization within electrophysiology ablation space

PFA technology is only marketed in Europe, and yet, it has been dominating the electrophysiology market by storm

AstraZeneca’s Tagrisso to lead lung cancer small molecule market with over $7 billion sales by 2029, says GlobalData

Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio

Mitsui invests in Lokavant Holdings

Lokavant provides clinical trial intelligence

Emmes acquires VaxTRIALS

VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth